What was studied?
The US trial randomized 281 adults with type 2 diabetes to retatrutide groups, placebo or an active dulaglutide comparator. The primary assessment was glycated hemoglobin change at 24 weeks.
What did the researchers report?
Most retatrutide groups improved glycated hemoglobin more than placebo, with weight changes also reported. Results varied by study group; gastrointestinal adverse events were frequent.
What are the limits?
The study was relatively small and short, and comparisons were with specific regimens. It does not settle long-term outcomes or support treating every result as a benefit shared by all triple-receptor compounds.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.